ExCeL, London, UK
Miltenyi Biotec Booth #71
March 17–18, 2026 | London, UK
Miltenyi Biotec powers the next generation of cell and gene therapies with an integrated platform combining manufacturing, analytics, and services designed to move programs faster – from early development through commercial readiness. Built on decades of real-world CGT experience, our solutions help you to reduce complexity, shorten timelines, and de-risk scale-up.
Meet us at booth #71 at the Advanced Therapies Congress to see how expert-guided, end-to-end workflows accelerate cell manufacturing, enable data-driven decisions, and keep your program on track toward CGT commercialization.
Scroll down to explore our technologies and services – from scalable cell manufacturing and in-process analytics to GMP-ready CDMO capabilities – engineered to support rapid clinical programs, regulatory confidence, and commercial execution.
Let’s accelerate your CGT journey.
We look forward to connecting with you in London.
ExCeL, London, UK
Miltenyi Biotec Booth #71
March 17–18, 2026 | Exhibit Hall opening hours
Tuesday, March 17 | 9 a.m. – 5:30 p.m.
Wednesday, March 18 | 9 a.m. – 4:30 p.m.
ExCel, London
Innovation (Track 2)
Abstract
Delivering genes selectively to defined cell populations using targeted lentiviral vectors (LVVs) is a promising strategy for next-generation immunotherapies, such as chimeric antigen receptor (CAR) T cell therapy. Conventional CAR T cell manufacturing requires multiple ex vivo manipulation steps over the course of up to two weeks. Streamlining this process or enabling direct in vivo CAR T cell generation could substantially reduce complexity while improving product quality.
We developed a novel paramyxovirus-pseudo-typed lentiviral vector (LVV) platform designed for efficient gene transfer into non-activated T cells ex vivo and in vivo. In this system, viral binding and fusion are mediated by the engineered hemagglutinin (H) and fusion (F) glycoproteins. Mutation of the H glycoprotein abolishes natural tropism, and fusion to cell-specific single-chain variable fragments (scFvs) or heavy-chain variable domains (VHHs) enables targeted transduction. Using this approach, we generated CD4-, CD8-, and pan-T-cell-specific LVVs. Compared with previously published systems, including measles virus–pseudo-typed LVVs, the paramyxovirus-pseudo type exhibited increased titers and improved production characteristics.
Using these targeted LVVs, we efficiently generated CAR T cells in vitro that demonstrated robust tumor-cell lysis across multiple constructs. In vivo evaluation was performed by administering a single dose of the targeted LVV into PBMC-transplanted NSG mice. This resulted in the selective transduction of T cell subsets and concurrent B cell depletion, confirming the successful generation and function of CAR T cells in vivo.
In summary, our optimized targeted LVV platform enables the selective and efficient delivery of genes to both activated and non-activated T cells in vitro and in vivo. This technology supports the controlled generation of defined CAR T cell subsets, providing a foundation for simplified, rapid, and potentially in vivo-based CAR T cell therapies.
Do you want to get in contact with us? Send your inquiry to:
Bukurie Zhuleku
Product Manager – CliniMACS® Disposables